CSL112: Phase IIa data

A double-blind, placebo-controlled, U.S. Phase IIa trial in 44 patients with stable atherothrombotic disease showed that single doses of 1.7, 3.4 and 6.8 g CSL112 were well tolerated with no clinicall...